Angioblast Loses Contract Counterclaims Against UBS
By Lisa Uhlman · February 2, 2012, 5:15 PM EST
A New York state judge on Monday dismissed stem cell research firm Angioblast Systems Inc.'s allegations that UBS Securities LLC is not entitled to $7.8 million in transaction fees related to...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login